Your search for major depressive disorder returned 38 results

Investigators searched publication databases for randomized controlled trials evaluating cognitive training and remediation interventions among patients with MDD.

Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.

Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.

Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.

This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.

Patients with and without ADHD were recruited for this cross-sectional, pragmatic, observational study.

Patients with MDD were randomly assigned in a 1:1:1 ratio to receive 1.5 mg daily cariprazine, 3.0 mg daily cariprazine, or placebo for 6 weeks.

The Alpha-Stim-D trial was a noncommercial, multicenter, randomly assigned, parallel group, double-blind trial conducted at 25 primary care practices in the United Kingdom.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

A cross-sectional family study sought to determine if parents’ transmission of anxiety is sex specific.

Inpatients with persistent depressive disorder were recruited at a German University Hospital for a 10-week inpatient treatment with the Cognitive Behavioral Analysis System of Psychotherapy.

For this study, patients with generalized anxiety disorder were recruited from the Nanfang Hospital in China between 2018 and 2020.

In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.

Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.

Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.

The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.

Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.

A placebo-controlled study of smokers with MDD evaluated varenicline with vs without behavioral interventions for smoking cessation.

A study was conducted to determine the effects of switching or augmenting antidepressant therapy in adults with treatment-resistant depression.

Patients who had treatment-naïve MDD were recruited in the US between 2007 and 2013 for the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study.

In this review, authors focused on the psychiatric issues that often accompany migraine and the effects of botulinum toxin A on migraine.

Investigators looked into which treatment fared better for patients with anxiety disorders: a mindfulness-based stress reduction intervention or escitalopram.

Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.

This retrospective cohort study evaluated patient data from patients aged 50 years or older who received an acute course of ECT between 2011 and 2019 and were evaluated for cognition and depression outcomes on the basis of baseline cognitive function.

Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.

Major depressive episodes reduce visual contrast suppression among patients with depressive disorders, a study shows.

This genome-wide associated study expanded on the gene-environment correlation for childhood maltreatment and causal relationship between childhood maltreatment and health.

Given the ethnic and racial disparities in the US, researchers examined whether SDoH contributed to racial and ethnic disparities in cognition, health, and depression.